| Objective: To observe the expressions of the endogenous cannabinoid receptors CB1 and the hydrolytic enzymes FAAH in the endometrium at different menstrual phase in normal women and polycystic ovary syndrome patients, and compare the differences. Through this study, investigate the relationship between the endocannabinoid system and polycystic ovary syndrome,and explore the pathogenesis of polycystic ovary syndrome at molecular level. Try to provide a new clinical thought of the disease. Methods:Selected patients who were treated in the Reproductive Center of Second Hospital of Hebei Medical University from October 2014 to January 2015, including 59 cases of PCOS(experimental group),and 54 non-PCOS patients(control group).They were randomly selected. The average age was 27±4 and 28±5 respectively. All the patients had no heart, liver, kidney, thyroid-related diseases, had no ovary or uterus surgery, had no steroids drug use in the last three months, had no hydrosalpinx history which may affect the endometrium. All patients were negative urine HCG. All PCOS specimens were send to pathology test to determine stage.The Endometrial tissue was fixed in 4% paraformaldehyde, dehydrated by ethanol and embedded in paraffin. The slice thickness was 3-5um, 5 slices per specimen were immunohistochemistry stained and analysised by the integrated optical density, obtained tissue samples CB1 and FAAH content. Analysised the experimental data with SPSS software package. Results: 1 CB1 and FAAH mainly expressed in endometrial epithelial cytoplasm 2 The average expression of CB1 in PCOS’s endometrium during the menstrual period, the proliferative phase, the secretory phase were: statistically significant(P<0.05); in the secretory phase were 385.71±128.66、480.73±132.05, the difference is statistically significant(P <0.05). Conclusions: 1 female endometrial endogenous cannabinoid receptors CB1 and FAAH enzyme hydrolysis is expressed mainly in the cytoplasm of the glandular epithelium. CB1’s expression in the endometrial tissue has no relationship with women’s menstrual cycle. FAAH ’s expression in the endometrial tissue is related with the menstrual cycle phase, expression was increased in the amount from the proliferative phase to the secretion phase,indicating that within the endometrium after ovulation endocannabinoid concentrations are at low concentration levels, which may have conducive to embryo implantation. 2 PCOS endometrium CB1 receptor expression in normal women has no significant difference, indicating that CB1 may not play a major role in the onset and evolution of disease polycystic ovary syndrome. The average expression in patients with polycystic ovary syndrome, endometrial tissue volume FAAH in proliferative and secretory phase was significantly lower than normal women, indicating a high concentration of endogenous cannabinoid levels may be caused by non-ovulation in patients with polycystic ovary syndrome infertility, or it is another reason for difficult embryo implantation after ovulation. 3 endocannabinoid system may be involved in the pathogenesis of polycystic ovary syndrome and the evolution of the disease, regulation and control of the system may become a new target for the treatment of polycystic ovary syndrome.334.85±130.63, 345.03±87.91, 382.94±117.82, there is no significant difference between the average expression level of each group(P>0.05). The average expression of the non-PCOS’s CB1 during the menstrual period, the proliferative, and the secretory phase were: 280.03±92.83,303.77±56.64,309.62±109.34, there is no significant difference between the average expression level of each group(P>0.05). 3 The average expression of FAAH in PCOS’s endometrium during the menstrual period, the proliferative phase, secretory phase were: 269.11±74.01,298.32±114.52,385.71±128.66, the difference was statistically significant(P<0.05).The difference between the secretory phase and the menstrual period was statistically significant(P <0.05), between the secretory phase and the proliferative phase was statistically significant(P <0.05),between the proliferative phase and the menstrual period had no statistically significant(P>0.05).The average expression of non-PCOS’s FAAH during the menstrual period, the proliferative, and the secretory phase were: 317.18±99.47,372.71±116.83,480.73±132.05, the difference was statistically significant(P<0.05). The difference between the secretory phase and the menstrual period was statistically significant(P<0.05), between the secretory phase and the proliferative phase was statistically significant(P <0.05), between the proliferative phase and the menstrual period had no statistically significant(P> 0.05), 4 The average expressions of CB1-positive tissue of the PCOS group and the non-PCOS group in menstrual period endometrium were 334.85±130.63、280.03±92.83, no significant difference(P>0.05); in the proliferative phase were 355.10 ± 127.46, 268.60 ± 73.40, no significant difference(P>0.05); in the secretory phase were 382.94±117.82 、309.62±109.34, no significant difference(P>0.05). 5 The average expressions of FAAH-positive tissue of the PCOS group and the non-PCOS group in menstrual period endometrium were 269.11±74.01 、 317.18±99.47, no significant difference(P>0.05); in the proliferative phase were 298.32±114.52、372.71±116.83, the difference is... |
PDF Full Text Request